An LT-B-ST (LT-B/ST) fusion peptide was constructed by genetically joining the 5' terminus of a synthetic gene coding for the heat-stable enterotoxin (ST) ofEscherichia coli to the 3' terminus of the gene coding for the binding subunit of the heat-labile enterotoxin (LT-B) ofE. coli. An eight-amino-acid, proline-containing linker was included between the LT-B and ST moieties. An aroA mutant of Salmonella dublin transformed with a plasmid carrying this genetic construct was shown to express a fusion peptide with antigenic determinants of both LT-B and ST. Mice were immunized orally with this strain or with a control strain expressing just LT-B from the same plasmid. Sera and mucosal secretions were obtained and analyzed for the presence of serum immunoglobulin G and mucosal immunoglobulin A that were able to recognize LT-B and ST by enzyme-linked immunosorbent assay (ELISA) and, more importantly, were able to neutralize native ST in the suckling mouse assay. Sera and mucosal secretions from animals immunized with the strain expressing the LT-B/ST fusion exhibited detectable ELISA reactivity against LT-B but not against native ST. However, even in the absence of detectable ELISA reactivity, both sera and mucosal secretions from these animals were able to neutralize the biological activity of native ST in the suckling mouse assay. These findings are important because they demonstrate the development of mucosal protection against ST by oral immunization with a genetic fusion delivered by a bacterial vector.
Escherichia coli causes diarrheal disease by a variety of mechanisms, including production of one or more enterotoxins. In addition to the high-molecular-weight, heat-labile enterotoxin (LT), E. coli may also produce a low-molecularweight (ca. 2,000), plasmid-mediated, heat-stable enterotoxin (ST) which functions by stimulating guanylate cyclase. The relative contribution of each enterotoxin to the global problem of E. coli-mediated diarrhea has never been clearly established. What is clear is that in some specific regions ST-producing E. coli organisms are the predominant enterotoxigenic E. coli organisms identified in indigenous populations as well as in foreign visitors to those areas. Furthermore, it is now clear that other genera of bacteria can produce enterotoxins immunologically related to both LT and ST, including Salmonella spp., noncholera vibrios, Yersinia spp., Klebsiella spp., Enterobacter spp., and Citrobacter spp. (22, 28, 35) . It is therefore important to include protection against ST in an overall program of complete immunological protection against enteric disease.
Because of its small size, ST tends to be poorly immunogenic. It can, however, become immunogenic when coupled to an appropriate carrier in a standard hapten-carrier configuration. Furthermore, ST can be chemically coupled to either LT or its binding subunit, LT-B. Not only is the product of such a coupling immunogenic, but the toxicity of the ST molecule may be reduced as a function of the cross-linking (27) . As an alternate approach to the development of a suitable ST toxoid, a number of research groups have constructed genetic fusions between ST and one or more subunits of cholera enterotoxin or LT (9, 23, (36) (37) (38) . These fusion polypeptides have many potential advantages * Corresponding author. over chemically derived conjugates, including a precisely defined and homogeneous protein structure and the possibility of delivering the antigens via a live oral vaccine.
Because of the site of action of enterotoxigenic E. coli, an effective immunoprophylactic against ST must be capable of eliciting protective immunity at the level of the mucosal surfaces of the small bowel. One method for induction of antigen-specific mucosal antibodies is delivery of antigens to the gut-associated lymphoid tissues by use of avirulent derivatives of Salmonella spp. as carriers of plasmids that code for relevant determinants of foreign antigens. This has been shown to be an effective means of inducing significant serum and secretory antibody responses in a number of animal species, including humans (29, 30) , cattle (41) , sheep (31) , rabbits (34) , fowl (4, 5) , and mice (2, 3, 6, 10, 13, 16, 18-20, 25, 26, 33, 40) . The effectiveness of this system is attributed to the fact that these Salmonella spp. reach the Peyer's patches, where they present their array of antigens directly to the T and B lymphocytes of the gut-associated lymphoid tissues, thereby priming the mucosal immune system to produce antigen-specific immune responses. This has prompted many investigators to consider and test the use of live attenuated Salmonella spp. as carriers of genes coding for virulence determinants from other pathogenic microorganisms (recently reviewed by Cardenas and Clements [6] ).
We have reported previously the construction of a fusion peptide in which the 5' terminus of the gene coding for ST was genetically fused to the 3' terminus of the gene coding for the binding (B) subunit of LT (9 For determination of murine antibodies directed against LT-B resulting from the immunizations, microtiter plates were precoated with 1.5 ,ug of mixed gangliosides (type III) per well and then with 1 jig of purified LT-B per well (11) . For determination of antibodies directed against ST, microtiter plates were precoated with 1 ,ug of purified ST (a gift from Donald C. Robertson, University of Kansas, Lawrence) per well. Serum and mucosal secretions were obtained as described previously (13) . Briefly, the small intestine from the duodenum to the ileal-cecal junction was excised and homogenized in a solution containing 50 mM EDTA and 0.1 mg of soybean trypsin inhibitor per ml. Samples were homogenized with a Tekmar Tissuemizer, clarified by centrifugation, lyophilized, resuspended in 2 ml of TEAN buffer (0.05 M Tris, 0.001 M EDTA, 0.003 M NaN3, 0.2 M NaCl, pH 7.5) (12), dialyzed against TEAN buffer, and stored at -20°C until assayed. Serum was collected by cardiac puncture, prepared by centrifugation through serum separators (Becton Dickinson), and stored at -20°C until assayed.
Samples from immunized mice or control samples were serially diluted in PBS-Tween and added to the microtiter wells. The presence of serum anti-LT-B or anti-ST IgG was determined by using rabbit antiserum against mouse IgG conjugated to alkaline phosphatase. Mucosal anti-LT-B or anti-ST IgA was assayed with goat antiserum against mouse IgA (alpha chain specific) and then with rabbit antiserum against goat IgG conjugated to alkaline phosphatase. The assays for ST were developed with hyperimmune rabbit anti-ST as a control and then by substituting serum or mucosal samples from immunized mice and then the appropriate anti-mouse specific conjugate 
RESULTS
Construction of the LT-B:linker:ST gene fusion. The plasmid encoding LT-B was isolated from E. coli JM83(pJC217) (11) and modified to permit the downstream, in-frame insertion of DNA sequences for the expression of fusion peptides at the carboxy terminus of LT-B as described previously (9) . A polylinker containing restriction sites for the enzymes NcoI, StuI, and EcoRV and termination codons in all three reading frames was added. Additional restriction sites downstream from the original polylinker are present in the modified LT-B plasmid, including a unique HindIII site. Plasmid pJC700 is a pUC18 derivative containing a synthetic structural gene for ST cloned across the EcoRI and Sall sites of pUC18 and was used as the source of the ST gene (9) . A synthetic linker containing 24 nucleotides with NcoI-and EcoRI-compatible ends was constructed with nucleotides coding for two proline residues to ensure maximum expression of ST antigenicity. We have shown previously that, in the absence of such a linker, no ST antigen is detected in these LT-B:linker:ST fusions (9) .
The modified LT-B plasmid was digested with NcoI and HindIII to permit a forced cloning insertion of the ST gene and synthetic linker. Next, plasmid pJC700 was digested with EcoRI and HindIII and the ST gene was purified by electroelution. This ST gene fragment, together with the NcoI-EcoRI compatible linker, was inserted across the NcoI-HindIII region of the modified LT-B plasmid (Fig. 1) . This plasmid construct was designated pBL1, and the sequence was confirmed by dideoxy sequencing. The complete nucleotide sequence and inferred amino acid sequence of the fusion peptide with the eight-amino-acid linker are shown in Fig. 2 . This construct differs from our previous LT-B: linker:ST construct in that the current linker contains three additional nucleotides (chloramphenicol acetyltransferase= histidine) at the beginning of the linker. This change was made to facilitate ongoing studies in our laboratory investigating potential means of increasing the antigenicity and immunogenicity of the ST moiety. E. coli JM83 was transformed with plasmid pBL1, and transformants were shown by ELISA to synthesize LT-B-and ST-related antigen (Fig.  3) .
Immunogenicity of the LT-B/ST fusion peptide. We have shown previously that mice immunized parenterally with an LT-B:linker:ST fusion peptide developed serum antibodies capable of recognizing native ST and neutralizing the biological activity of ST in the suckling mouse assay. However, to be an effective immunogen, the fusion peptide would need to be administered in a manner capable of inducing protective antibodies on relevant mucosal surfaces. In order to accomplish this, an attenuated aro mutant of S. dublin was transformed with plasmid pBL1. Transformants were screened for expression of LT-B-and ST-related antigen by ELISA. One LT-B-ST (LT-B/ST) antigen-positive transformant, designated S. dublin(pBL1), was selected and used to immunize groups of BALB/c mice orally.
Mice were immunized orally with this strain or with a control strain expressing just LT-B from the same plasmid. Sera and mucosal secretions were obtained and analyzed for the presence of serum IgG and mucosal IgA that were able to recognize LT-B and ST by ELISA and, more importantly, to neutralize native ST in the suckling mouse assay. Sera and mucosal secretions from animals immunized with S. dublin-(pBL1) expressing the LT-B:linker:ST fusion exhibited detectable ELISA reactivity against LT-B but not native ST. The serum IgG anti-LT-B response in this group of animals was 150 + 56 ,ug/ml, and the mucosal IgA anti-LT-B response was 513 + 119 ng/ml. There was no ELISA-detectable serum or mucosal anti-ST in these animals. However, even in the absence of detectable ELISA reactivity against ST, both sera and mucosal secretions from these animals were able to neutralize the biological activity of native ST in the suckling mouse assay (Fig. 4) . The biological activity of ST was partially neutralized by sera and completely neutralized by mucosal secretions from animals immunized orally with S. dublin(pBL1). ST was not neutralized by control sera or mucosal secretions or samples from normal unimmunized mice. These findings are important because they demonstrate the development of mucosal protection against ST by oral immunization with a genetic fusion delivered by a bacterial vector. They also demonstrate that this system can be used to elicit a protective immune response against antigens that are not normally immunogenic but which can be made immunogenic when genetically fused to an appropriate carrier. DISCUSSION E. coli ST is an important virulence determinant in enterotoxin-mediated diseases caused by E. coli. However, the small size and poor immunogenicity of the molecule have hampered any serious study to determine whether immunization against ST can significantly influence the occurrence of diarrheal disease due to organisms that produce this toxin. There TGT TAT GTT TTA  1T-ACG GCG  met  asn   lys  val  lys  cys  tyr  val  leu  phe  thr  ala   TTA CTA TCC TCT CTA TGT GCA TAC GGA GCT CCC CAG  leu  leu  ser  ser  leu  cys  ala  tyr  gly  ala (27) and without toxicity. Immunogenicity of the fusion peptide was the construction of genetic fusions between ST and one or demonstrated in animals immunized parenterally with either more subunits of cholera enterotoxin and LT (9, 23, (36) (37) (38) .
crude or purified preparations containing the hybrid moleIn general, these genetic fusions have either retained some cule. Sera from these animals contained antibodies that were degree of ST-associated toxicity or been incapable of elicitable to recognize native ST in vitro and neutralize the ing neutralizing antibodies. Moreover, none of these fusion biological activity of ST in the suckling mouse assay.
polypeptides has been shown to be effective at eliciting
An important aspect of these earlier genetic fusion studies mucosal antibodies that could either recognize ST antigeniwas the finding that maximum antigenicity of the fused cally or neutralize the biological activity of ST in a relevant peptide was obtained when an appropriate linker was inanimal model.
cluded between the LT-B and ST moieties. Presumably, the We have reported previously the construction of a fusion included proline residues interrupt the cL-helix and create a peptide in which the 5' terminus of the gene coding for ST rigid kink or bend which affects the flexibility and antigenicwas genetically fused to the 3' terminus of the gene coding ity of the fused antigen. In the present study, we developed for LT-B (9). The LT-B and ST moieties were joined with a a second LT-B:linker:ST construct in which an eight-aminoseven-amino-acid, proline-containing linker. This LT-B:linkacid, proline-containing linker was included between LT-B er:ST gene fusion coded for production of a fusion polypepand ST. The primary aim of the study reported here was to (7, 14, 15) . One application of this approach has been to employ avirulent derivatives of Salmonella spp. as carriers for plasmids that code for antigenic determinants of heterologous mucosal pathogens. This technique has been examined with a number of antigens and has been shown to be an effective means of stimulating significant levels of specific mucosal secretory IgA directed against the carrier strain and the foreign antigen. In the study reported here, an aroA mutant of S. dublin was transformed with the LT-B:linker:ST fusion plasmid and used to immunize mice orally. Sera and mucosal secretions from animals immunized with this strain exhibited detectable ELISA reactivity against LT-B but not native ST. However, even in the absence of detectable ELISA reactivity, both sera and mucosal secretions from these animals were able to neutralize the biological activity of native ST in the suckling mouse assay. These findings constitute the first demonstration of the development of mucosal antibody capable of neutralizing ST by oral immunization with a genetic fusion delivered by a bacterial vector.
There are a number of possible explanations for the observed neutralization in the absence of a detectable ELISA response. In the first place, the ST moiety in the fusion peptide will undoubtedly assume a conformation different from that of native ST, so antibodies developed against the fusion peptide may not recognize native ST in a strictly antigen-driven assay such as the ELISA. It should be noted that antibodies to native ST do recognize ST antigen in the fusion peptide, implying some level of cross-reactivity. In addition, the critical factor for neutralization is development of antibodies directed against epitopes associated with toxicity (i.e., neutralizing antibodies). In these genetic fusions, ST The purpose of the study reported here was to test the ability of an LT-B:linker:ST fusion peptide to elicit mucosal protection against ST. Such an immunogen may be useful as one component of a live, oral, multivalent vaccine for typhoid fever, cholera, and the cholera-related enteropathies, such as enterotoxigenic E. coli.
